Earnings ·
Reports Q3 revenue of $4.4B and raises full-year outlook to $16.7–$17.0 billion
TEVATeva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. reported third-quarter revenues of $4.4 billion, a 2% decline year-over-year driven by lower generic sales, primarily lenalidomide capsules in the U.S. The company raised its full-year revenue outlook to $16.7–$17.0 billion from $16.5–$16.85 billion and increased guidance for key innovative brands AUSTEDO, AJOVY, and UZEDY. GAAP diluted EPS was $0.20, while non-GAAP diluted EPS reached $0.86. The firm also announced the FDA approval of WELTRUZA for schizophrenia and acquired BXCL-501 from BioXcel Therapeutics. Teva operates as a global pharmaceutical company specializing in generic medicines, biosimilars, and innovative therapies.